{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"487"},{"groupId":"OG001","value":"483"}],"units":"Participants"}],"description":"Will be reported as count of participants who have experienced an EFS event or death at two years.\n\nEFS Events are defined as:\n\n* Disease progression/relapse\n* Administration of non-protocol specified systemic anti-lymphoma therapy (i.e. salvage therapy) at any time after initiation of protocol therapy.\n* Administration of any non-protocol specified radiation therapy at any time afterinitiation of protocol therapy Will be estimated using Kaplan-Meier method and compared between treatment arms using cox regression model.","groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.\n\nBiospecimen Collection: Undergo peripheral blood collection\n\nComputed Tomography: Undergo PET/CT or CT scan\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFilgrastim: Given SC or IV\n\nMagnetic Resonance Imaging: Undergo MRI\n\nNivolumab: Given IV\n\nPegfilgrastim: Given SC\n\nPositron Emission Tomography: Undergo PET/CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies\n\nRadiation Therapy: Receive radiation therapy\n\nVinblastine Sulfate: Given IV","id":"OG000","title":"Arm I (Chemotherapy, Nivolumab, Radiation)"},{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician. Patients also undergo peripheral blood specimen collection and CT, PET/CT and MRI on study.\n\nBiospecimen Collection: Undergo peripheral blood collection\n\nBrentuximab Vedotin: Given IV\n\nComputed Tomography: Undergo PET/CT or CT scan\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nFilgrastim: Given SC or IV\n\nMagnetic Resonance Imaging: Undergo MRI\n\nPegfilgrastim: Given SC\n\nPositron Emission Tomography: Undergo PET/CT scan\n\nQuality-of-Life Assessment: Ancillary studies\n\nQuestionnaire Administration: Ancillary studies\n\nRadiation Therapy: Receive radiation therapy\n\nVinblastine Sulfate: Given IV","id":"OG001","title":"Arm II (Chemotherapy, Brentuximab Vedotin, Radiation)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All the patients who underwent randomization except for those who were deemed to be ineligible by pathology review or owing to violation of the eligibility criteria.","reportingStatus":"POSTED","timeFrame":"From date of registration to date of first occurrence of EFS event, assessed at 2 years","title":"Event-free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Participants"}